JSKN-003

CSPC Pharmaceutical's SYS6010 receives Breakthrough Therapy Designation from China's NMPA for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

Alphamab Oncology's JSKN003, an anti-HER2 bispecific ADC, enters Phase III trial for platinum-resistant recurrent ovarian cancer, comparing its efficacy against chemotherapy.

Alphamab Oncology's JSKN033, a subcutaneous co-formulation of anti-HER2 bispecific ADC and PD-L1 inhibitor, has been included in Shanghai's pilot program for innovative drug clinical trials.

Alphamab Oncology has retracted its press release regarding the inclusion of JSKN033, an anti-HER2 bispecific antibody-drug conjugate (ADC), in a pilot program.

Alphamab Oncology's JSKN033, a subcutaneous co-formulation of anti-HER2 bispecific ADC and PD-L1 inhibitor, has been included in Shanghai's pilot program for accelerated clinical trial review.